Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
June 13, 2016 7:30 AM EDTCareDx at the Forefront of Personalized Medicine in Transplantation
CareDx to hold Conference Call on June 13, 2016 at 4pm ET
BRISBANE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, reported the first results of increased levels of donor-derived cell-free DNA (dd-cfDNA) with acute kidney rejection to the DART study clinical investigators attending the American Transplant Congress. The study demonstrated increased levels of dd-cfDNA in acute rejection using the... More
